Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.

Chan M, Chang MC, González R, Lategan B, del Barco E, Vera-Badillo F, Quesada P, Goldstein R, Cruz I, Ocana A, Cruz JJ, Amir E.

PLoS One. 2015 Jul 10;10(7):e0132449. doi: 10.1371/journal.pone.0132449.

2.
3.

Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Iorfida M, Mazza M, Balduzzi A, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M.

Ann Oncol. 2013 Mar;24(3):661-8. doi: 10.1093/annonc/mds430.

PMID:
23022996
4.
5.

Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.

Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO.

J Clin Oncol. 2007 Oct 20;25(30):4772-8.

PMID:
17876012
6.

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.

Regan MM, Pagani O, Francis PA, Fleming GF, Walley BA, Kammler R, Dell'Orto P, Russo L, Szőke J, Doimi F, Villani L, Pizzolitto S, Öhlschlegel C, Sessa F, Peg Cámara V, Rodríguez Peralto JL, MacGrogan G, Colleoni M, Goldhirsch A, Price KN, Coates AS, Gelber RD, Viale G; SOFT and TEXT Investigators and International Breast Cancer Study Group..

Breast Cancer Res Treat. 2015 Nov;154(2):275-86. doi: 10.1007/s10549-015-3612-z.

7.
8.

Impact of triple negative phenotype on breast cancer prognosis.

Kaplan HG, Malmgren JA.

Breast J. 2008 Sep-Oct;14(5):456-63. doi: 10.1111/j.1524-4741.2008.00622.x.

PMID:
18657139
9.

Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.

Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, Kim SW, Lee JE, Nam SJ.

BMC Cancer. 2015 Mar 18;15:138. doi: 10.1186/s12885-015-1121-4.

10.

Is triple negative a prognostic factor in breast cancer?

Nishimura R, Arima N.

Breast Cancer. 2008;15(4):303-8. doi: 10.1007/s12282-008-0042-3.

PMID:
18369692
11.

Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.

Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S, Sotiropoulou M, Filippidis T, Gogas H, Koletsa T, Bafaloukos D, Televantou D, Kalogeras KT, Pectasides D, Skarlos DV, Koutras A, Dimopoulos MA.

PLoS One. 2012;7(6):e37946. doi: 10.1371/journal.pone.0037946.

12.

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.

Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A.

J Clin Oncol. 2008 Mar 1;26(7):1059-65. doi: 10.1200/JCO.2007.12.9437.

PMID:
18227529
13.

Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.

Cortesi L, De Matteis E, Cirilli C, Marcheselli L, Proietto M, Federico M.

Tumori. 2012 Nov;98(6):743-50. doi: 10.1700/1217.13498.

PMID:
23389361
14.

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.

Yu KD, Di GH, Wu J, Lu JS, Shen KW, Liu GY, Shen ZZ, Shao ZM.

J Cancer Res Clin Oncol. 2008 Dec;134(12):1347-54. doi: 10.1007/s00432-008-0414-2.

PMID:
18488249
15.

Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research.

Alqaisi A, Chen L, Romond E, Chambers M, Stevens M, Pasley G, Awasthi M, Massarweh S.

Breast Cancer Res Treat. 2014 Nov;148(2):437-44. doi: 10.1007/s10549-014-3145-x.

PMID:
25257728
16.

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.

Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L, Bergh J.

Med Oncol. 2009 Dec;26(4):480-90. doi: 10.1007/s12032-008-9157-9.

PMID:
19130322
17.

Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.

Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N.

World J Surg Oncol. 2011 Oct 17;9:131. doi: 10.1186/1477-7819-9-131.

18.

Estrogen receptor positive operable breast cancer: does menopausal status impact on HER2 and progesterone receptor status?

Wang N, Wang B, Wang Y, Hu J.

Breast. 2011 Dec;20(6):519-24. doi: 10.1016/j.breast.2011.05.009.

PMID:
21700456
20.

Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.

Chen X, Yuan Y, Gu Z, Shen K.

Breast Cancer Res Treat. 2012 Aug;134(3):957-67. doi: 10.1007/s10549-012-1990-z.

PMID:
22370627
Items per page

Supplemental Content

Support Center